No question this partnership is a real plus. If this company had no cred,...then Teva would not be our partner. This partnership will payoff nicely as we go along here IMO! Shorts will start to get nervous here as the clock tics closer to q4. They will not want to take a chance on being here when the unblinding happens. I liken it to shorts not wanting to short companies that are likely to get bought out in any industry. That is always an option here as well. My point is,...shorts will start to cover soon IMO, as they won't want to take on more risk at this juncture and buyers will be coming in to position themselves ahead of Q4 when Abstral launches here in the US. Also ahead of the unblinding most likely in Q1-14. Anything under $2 is a huge gift IMO. Position yourselves accordingly!